INTRODUCTION: Patient-reported outcomes (PROs) are the gold standard to describe subjective symptoms. Nurses can be successfully involved in collecting symptom information, because of their direct relationship with the patient. In order to improve clinical management of outpatients receiving active anti-cancer treatment, we introduced in routine clinical practice an assessment of patient-reported symptoms and toxicities, starting from January 2018. Our hypothesis was that this could help to better control symptoms, improving patients' quality of life (QoL). METHODS: Eligible patients were receiving an active anti-cancer treatment, as outpatients. Patients included in the control group (treated in 2017) underwent "usual" visits (group A), while patients treated in 2018, before each visit received a questionnaire by a dedicated nurse, in order to provide information about symptoms and toxicities (group B). Primary objective was the comparison of QoL changes, measured by EORTC QLQ-C30. RESULTS: A total of 211 patients have been analyzed (119 group A; 92 group B). After 1 month, mean change from baseline of global QoL was - 1.68 in group A and + 2.54 in group B (p = 0.004, effect size 0.20). Group B showed significantly better mean changes for fatigue, pain, and appetite loss. Proportion of patients obtaining a clinically significant improvement in global QoL score was higher in group B (32.6%) compared to group A (19.3%, p = 0.04). Patients' satisfaction with questionnaire was high. CONCLUSION: Introduction of PROs in clinical practice, thanks to an active role of nurses, was feasible, produced high patients' satisfaction and a significant QoL improvement, compared to the traditional modality of visit.
INTRODUCTION:Patient-reported outcomes (PROs) are the gold standard to describe subjective symptoms. Nurses can be successfully involved in collecting symptom information, because of their direct relationship with the patient. In order to improve clinical management of outpatients receiving active anti-cancer treatment, we introduced in routine clinical practice an assessment of patient-reported symptoms and toxicities, starting from January 2018. Our hypothesis was that this could help to better control symptoms, improving patients' quality of life (QoL). METHODS: Eligible patients were receiving an active anti-cancer treatment, as outpatients. Patients included in the control group (treated in 2017) underwent "usual" visits (group A), while patients treated in 2018, before each visit received a questionnaire by a dedicated nurse, in order to provide information about symptoms and toxicities (group B). Primary objective was the comparison of QoL changes, measured by EORTC QLQ-C30. RESULTS: A total of 211 patients have been analyzed (119 group A; 92 group B). After 1 month, mean change from baseline of global QoL was - 1.68 in group A and + 2.54 in group B (p = 0.004, effect size 0.20). Group B showed significantly better mean changes for fatigue, pain, and appetite loss. Proportion of patients obtaining a clinically significant improvement in global QoL score was higher in group B (32.6%) compared to group A (19.3%, p = 0.04). Patients' satisfaction with questionnaire was high. CONCLUSION: Introduction of PROs in clinical practice, thanks to an active role of nurses, was feasible, produced high patients' satisfaction and a significant QoL improvement, compared to the traditional modality of visit.
Entities:
Keywords:
Patient-reported outcomes; Quality of life; Side effects; Toxicity
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Timothy J Judson; Antonia V Bennett; Lauren J Rogak; Laura Sit; Allison Barz; Mark G Kris; Clifford A Hudis; Howard I Scher; Paul Sabattini; Deborah Schrag; Ethan Basch Journal: J Clin Oncol Date: 2013-06-03 Impact factor: 44.544
Authors: O Honma; C Watanabe; H Fukuchimoto; J Kashiwazaki; M Tateba; S Wagatsuma; K Ogata; K Maki; H Sonou; K Shiga; E Otsuka; M Hiruta; Y Hirasawa; M Hosonuma; M Murayama; Y Narikawa; H Toyoda; T Tsurui; A Kuramasu; M Kin; Y Kubota; T Sambe; A Horiike; H Ishida; K Shimada; M Umeda; T Tsunoda; K Yoshimura Journal: Front Pharmacol Date: 2022-02-09 Impact factor: 5.810
Authors: Veronica Agostinelli; Chiara De Filippis; Mariangela Torniai; Marco Bruno Luigi Rocchi; Alessandra Pagliacci; Giulia Ricci; Rosina Corsi; Paolo Luzi; Michele Caporossi; Rossana Berardi Journal: Cancer Med Date: 2022-06-27 Impact factor: 4.711
Authors: Valeria Sanna; Palma Fedele; Giulia Deiana; Maria G Alicicco; Chiara Ninniri; Anna N Santoro; Antonio Pazzola; Alessandro Fancellu Journal: World J Clin Oncol Date: 2022-07-24